Inflammatory myofibroblastic tumor (IMFT) is a rare, transient tumor that occurs predominantly in children and young adults, although it can also occur in adults. This tumor is usually associated with inflammatory processes and appears as a benign neoplasm composed of myofibroblasts, intermediate cells between fibroblasts and smooth muscle cells. IMFT is often localized in the abdomen, lungs, and soft tissues, but can occur in other anatomical areas. The main clinical manifestations are pain and swelling in the tumor area. Since the tumor is benign, its development can be associated with various inflammatory processes, such as trauma or infection.
History of the disease and interesting historical facts
The first description of inflammatory myofibroblastic tumor was made in 1982, when researchers drew attention to tumor formations that were similar to other types of neoplasms, but differed in characteristic morphological and clinical features. Later, a connection between IMFT and chronic inflammatory processes was established, which led to additional research in this area. Interestingly, in the early stages of its study, this tumor was sometimes incorrectly classified as sarcoma or other malignancies due to the similarity of clinical characteristics. This circumstance emphasizes the importance of differential diagnosis.
Epidemiology
Inflammatory myofibroblastic tumor is considered a rare disease, the statistics of which vary greatly depending on the region. According to some studies, the incidence of IMFT is approximately 0.1-0.5% of all cases of benign tumors. Epidemiological studies show that most cases are observed in children under 14 years of age, with about 50% of them being children under three years of age. Adults make up a smaller proportion, but can develop IMFT at any age. Sexual dimorphism is not observed, so both sexes suffer from this disease almost equally.
Genetic predisposition to this disease
There is no direct genetic predisposition to inflammatory myofibroblastic tumor. However, studies have shown that mutations in a number of genes associated with cell proliferation and inflammatory processes may participate in the pathogenesis of IMFT. The most frequently mentioned mutations are in the ALK genes and others that regulate cell migration and survival. Pathological changes in these genes may contribute to the formation of tumor cells that activate the inflammatory process.
Risk factors for the development of this disease
Certain factors may increase your risk of developing inflammatory myofibroblastic tumor, including:
- Trauma to the area where the tumor later develops.
- Chronic infections such as viral or bacterial.
- Exposure to chemicals, including carcinogens, that can initiate inflammatory responses.
- Systemic diseases that manifest as a chronic inflammatory process, such as autoimmune disorders.
Diagnosis of this disease
Diagnosis of inflammatory myofibroblastic tumor includes several stages and methods:
- Main symptoms: patients usually complain of local pain and swelling in the area of the tumor. Sometimes an elevated body temperature may be observed.
- Laboratory tests most often include a complete blood count, which may reveal signs of inflammation, such as an elevated white blood cell count.
- Radiological tests such as ultrasound, CT scan, and MRI can help visualize the location and size of the tumor and evaluate its structure.
- Other types of diagnostics may include a tumor biopsy to clarify its morphological nature.
- The differential diagnosis should exclude malignant tumors such as sarcomas, as well as other benign formations.
Treatment
Treatment of inflammatory myofibroblastic tumor typically includes several approaches:
- General treatment usually involves observation of the patient, as many tumors can regress on their own.
- Pharmacological treatment uses anti-inflammatory drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs), to reduce symptoms.
- Surgery may be necessary if there are significant symptoms or if the tumor is causing compression of nearby structures.
- Other treatments may include immunotherapy or observation without intervention if the tumor is small and does not cause clinical problems.
List of medications used to treat this disease
The main groups of drugs that can be used in the treatment of inflammatory myofibroblastic tumor:
- NSAIDs (eg, ibuprofen, diclofenac) to relieve inflammation and pain.
- Corticosteroids (in severe forms of the disease) to reduce inflammation.
- Immunosuppressants (in selected cases) to control inflammatory responses.
Disease monitoring
Monitoring of inflammatory myofibroblastic tumor includes regular examinations to assess the dynamics. Control stages may include:
- Complete blood counts every 3-6 months to monitor for signs of inflammation.
- Radiological examinations every six months to monitor changes in the size and structure of the tumor.
- The prognosis is generally favorable, since the tumor is benign and can often regress on its own.
- Complications, although rare, may include recurrence of the disease or the development of other inflammatory processes.
Age-related features of the disease
Inflammatory myofibroblastic tumor may have different presentations depending on the age of the patient. In children, long-term observation is usually sufficient, as many cases resolve spontaneously. In adults, IMFT may require a more aggressive approach to diagnosis and treatment, as there is a greater risk of misinterpretation of the clinical picture.
Questions and Answers
- What are the main symptoms of inflammatory myofibroblastic tumor? The main symptoms include localized pain and swelling, and possibly an increase in body temperature.
- Why is it important to conduct a differential diagnosis? Differential diagnosis is necessary to exclude malignant tumors and other conditions with similar clinical manifestations.
- How does tumor regression occur? In most cases, the tumor may disappear on its own due to the supposed regulation of the inflammatory process.
- What treatments are available for VMFO? Treatment may range from observation to surgery, depending on the clinical case.
- How dangerous is this tumor? Inflammatory myofibroblastic tumor is usually benign and rarely causes serious consequences.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov recommends paying special attention to symptoms such as prolonged pain and compaction in the affected area and not ignoring them. “It is important to monitor your sensations, especially if you notice new growths. Do not self-medicate, but rather consult a specialist for a comprehensive examination,” the doctor emphasizes. It is also recommended to conduct regular medical examinations to detect possible changes at an early stage.
